Drug intelligence / Profile preview

HT61

Development stage
Unknown
Lead developer
Helperby Therapeutics Group
Modality
Small Molecules
Administration
Intraperitoneal, Topical
01

Overview

**HT61** is a small quinolone-derived compound (molecular mass ~400 Da) with bactericidal activity against gram-positive bacteria, including methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* (MSSA and MRSA), particularly effective against non-multiplying cells and biofilms. It acts as a membrane-active antimicrobial by partitioning into the negatively charged bacterial lipid bilayer due to its cationic charge, causing structural disruption, membrane depolarization, loss of integrity, ATP leakage, and eventual cell lysis. HT61 demonstrates synergy with aminoglycosides (e.g., neomycin, gentamicin, tobramycin) and antiseptics (e.g., chlorhexidine, mupirocin), enhancing their efficacy against *S. aureus* and tobramycin-resistant *Pseudomonas aeruginosa* strains in vitro, in biofilms, and in murine models of skin and pulmonary infections, though it shows limited direct activity alone against gram-negative bacteria.[1][2][3][5][6]

02

Targets

Cardiolipin

Beyond the preview

Go deeper on HT61.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT61.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call